LI Taisheng
Quick facts
Marketed products
- cART · Oncology
cART is a chimeric antigen receptor T-cell therapy that engineers a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: